472 related articles for article (PubMed ID: 27861297)
21. Shaping of CD56
Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2019; 10():547. PubMed ID: 30949182
[TBL] [Abstract][Full Text] [Related]
22. Safety and Outcomes of Extracorporeal Photopheresis With the Therakos Cellex System for Graft-Versus-Host Disease in Pediatric Patients.
Uygun V; Daloglu H; Karasu G; Hazar V; Yeşilipek A
J Pediatr Hematol Oncol; 2015 Apr; 37(3):209-14. PubMed ID: 25374287
[TBL] [Abstract][Full Text] [Related]
23. "Best practice" for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa' Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers.
Pierelli L; Bosi A; Olivieri A
Transfusion; 2018 Jan; 58(1):217-222. PubMed ID: 29134658
[TBL] [Abstract][Full Text] [Related]
24. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.
Wang L; Ni M; Hückelhoven-Krauss A; Sellner L; Hoffmann JM; Neuber B; Luft T; Hegenbart U; Schönland S; Kleist C; Sill M; Chen BA; Wuchter P; Eckstein V; Krüger W; Hilgendorf I; Yerushalmi R; Nagler A; Müller-Tidow C; Ho AD; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2018; 9():2207. PubMed ID: 30349527
[TBL] [Abstract][Full Text] [Related]
25. Analysis of clinical outcome and survival in pediatric patients undergoing extracorporeal photopheresis for the treatment of steroid-refractory GVHD.
González Vicent M; Ramirez M; Sevilla J; Abad L; Díaz MA
J Pediatr Hematol Oncol; 2010 Nov; 32(8):589-93. PubMed ID: 20962677
[TBL] [Abstract][Full Text] [Related]
26. Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study.
Berger M; Albiani R; Sini B; Fagioli F
Transfusion; 2015 Apr; 55(4):736-47. PubMed ID: 25355659
[TBL] [Abstract][Full Text] [Related]
27. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients.
Perotti C; Del Fante C; Tinelli C; Viarengo G; Scudeller L; Zecca M; Locatelli F; Salvaneschi L
Transfusion; 2010 Jun; 50(6):1359-69. PubMed ID: 20113452
[TBL] [Abstract][Full Text] [Related]
28. Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience.
Niittyvuopio R; Juvonen E; Heiskanen J; Lindström V; Nihtinen A; Sahlstedt L; Volin L
Transfusion; 2018 Aug; 58(8):1973-1979. PubMed ID: 29707788
[TBL] [Abstract][Full Text] [Related]
29. Acute graft v host disease: developing an extracorporeal photopheresis outreach service.
Maher T; Taylor P; Alfred A
Br J Nurs; 2018 May; 27(9):488-492. PubMed ID: 29749783
[TBL] [Abstract][Full Text] [Related]
30. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
31. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis.
Jagasia M; Greinix H; Robin M; Das-Gupta E; Jacobs R; Savani BN; Engelhardt BG; Kassim A; Worel N; Knobler R; Russell N; Socie G
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1129-33. PubMed ID: 23623892
[TBL] [Abstract][Full Text] [Related]
32. Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy.
Bisaccia E; Palangio M; Gonzalez J; Adler KR; Scarborough R; Goldberg SL; Rowley SD
J Clin Apher; 2006 Oct; 21(3):181-7. PubMed ID: 16607632
[TBL] [Abstract][Full Text] [Related]
33. Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease.
Richet C; Huynh A; Dimeglio C; Borel C; Lepage B; Boulinguez S; Marguery MC; Paul C; Bulai Livideanu C
Dermatology; 2018; 234(1-2):23-30. PubMed ID: 29788024
[TBL] [Abstract][Full Text] [Related]
34. Extracorporeal photopheresis for the treatment of chronic graft versus host disease.
Kansu E; Ward D; Sanchez AP; Cunard R; Hayran M; Huseyin B; Vaughan M; Ku G; Curtin P; Mulroney C; Costello C; Castro JE; Wieduwilt M; Corringham S; Ihasz-Davis A; Nelson C; Ball ED
Hematology; 2022 Dec; 27(1):785-794. PubMed ID: 35802815
[TBL] [Abstract][Full Text] [Related]
35. Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda B; Solana-Altabella A; Cano I; Acuña-Cruz E; Rodríguez-Veiga R; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Gómez I; Solves P; Lorenzo I; Piñana JL; Sanz J; Guerreiro M; Montoro Gómez J; Díaz-González A; Marco J; Blanco A; Sanz MÁ; Montesinos P
J Clin Apher; 2021 Aug; 36(4):612-620. PubMed ID: 33964038
[TBL] [Abstract][Full Text] [Related]
36. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP).
Jagasia MH; Savani BN; Stricklin G; Engelhardt B; Kassim A; Dixon S; Chen H; Chinratanalab W; Goodman S; Greer JP; Schuening F
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1288-95. PubMed ID: 19747637
[TBL] [Abstract][Full Text] [Related]
37. Extracorporeal photopheresis performed on the CELLEX® compared with the UVAR-XTS® instrument is more efficient and better tolerated in children with steroid-refractory graft-versus-host disease.
Kapadia E; Wong E; Perez-Albuerne E; Jacobsohn D
Pediatr Blood Cancer; 2015 Aug; 62(8):1485-8. PubMed ID: 25881179
[TBL] [Abstract][Full Text] [Related]
38. Ocular manifestations of chronic graft-versus-host disease in patients treated with extracorporeal photochemotherapy.
Motolese E; Rubegni P; Poggiali S; Motolese PA; Marotta G; Russo L; D'Ascenzo G; Carcagni MR; Fruschelli M; Motolese I; Fimiani M
Eur J Ophthalmol; 2007; 17(6):961-9. PubMed ID: 18050124
[TBL] [Abstract][Full Text] [Related]
39. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.
Weitz M; Strahm B; Meerpohl JJ; Bassler D
Cochrane Database Syst Rev; 2014 Feb; (2):CD009898. PubMed ID: 24569961
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease.
Whittle RM; Denney H; Chantry AD; Alfred A; Taylor PC
J Clin Apher; 2017 Dec; 32(6):462-473. PubMed ID: 28608529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
